Takeda Pharmaceutical Files 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Jun 7, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, administrative
TL;DR
Takeda filed a 6-K on 6/7/24, confirming its reporting status and Tokyo HQ.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on June 7, 2024, to report information as a foreign private issuer. The filing indicates Takeda's principal executive offices are located in Tokyo, Japan, and confirms they file annual reports under Form 20-F.
Why It Matters
This filing serves as an official update from Takeda to the SEC, providing transparency on its status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine administrative filing by Takeda, not indicating any specific new risks or material events.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer
- 0001395064-24-000062 (filing_id) — Accession Number
- 001-38757 (company_id) — Commission File Number
- 20240607 (date) — Filing Date
- Tokyo (location) — Principal Executive Offices
FAQ
What type of SEC filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the filer of this report?
The filer is Takeda Pharmaceutical Company Limited.
When was this report filed?
The report was filed on June 7, 2024.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
Under which form does Takeda file its annual reports?
Takeda files its annual reports under Form 20-F.
Filing Stats: 1,452 words · 6 min read · ~5 pages · Grade level 14.4 · Accepted 2024-06-07 06:04:22
Filing Documents
- form6k-1_060724.htm (6-K) — 38KB
- 0001395064-24-000062.txt ( ) — 39KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date June 7, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release Notice Regarding Pricing of JPY Hybrid Bonds OSAKA, Japan, June 7, 2024 – Takeda Pharmaceutical Company Limited (Head Office Chuo-ku, Osaka (TSE4502NYSETAK), " Takeda ") announced that its 2 nd Unsecured, Interest Deferrable and Early Redeemable Subordinated Bonds ("the 2 nd Hybrid Bonds") with an aggregate principal amount of JPY 460 billion were priced today. The proceeds from the 2 nd Hybrid Bonds will be applied towards the redemption of Takeda's 1 st Unsecured, Interest Deferrable and Early Redeemable Subordinated Bonds ("the 1 st Hybrid Bonds") on their First Call Date of October 6, 2024. Overview of the 2 nd Hybrid Bonds 1. Issue Amount JPY 460 billion 2. Interest Rate 1.934% per annum (See Note (i) below) 3. Issue Date June 25, 2024 4. Maturity Date June 25, 2084 5. Interest Payment Dates December 25, 2024, for the first payment and thereafter semi-annually on June 25 and December 25 of each year (or, in the case of an early redemption, the early redemption date). 6. Early Redemption Takeda may redeem the 2 nd Hybrid Bonds at its discretion on each interest payment date from and including June 25, 2029 or in case where a Tax Event or an Equity Credit Change Event occurs. 7. Deferral of Interest Payment Takeda may, at its discretion, defer all or some of the payment of interest on the 2 nd Hybrid Bonds, subject to mandatory payment clauses. 8. Subordination In liquidation proceedings, bankruptcy proceedings, reorganization proceedings, rehabilitation proceedings and similar proceedings in accordance with laws other than the laws of Japan, the 2 nd Hybrid Bonds will be subordinate to all
Forward-Looking Statements
Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States competitive pressures and developments changes to applicable laws and regulations challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof uncertainty of commercial success for new and existing products manufacturing difficulties or delays fluctuations in interest and currency exchange rates claims or concerns regarding the safety or efficacy of marketed products or product candidates the impact of health crises, like the novel coronavirus pandemic the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits and other factors ident